Home › Compare › ALVNF vs ABBV
ALVNF yields 35.71% · ABBV yields 3.06%● Live data
📍 ALVNF pulled ahead of the other in Year 1
Combined, ALVNF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ALVNF + ABBV for your $10,000?
Alviva Holdings Limited provides information and communication technology (ICT) products and services in South Africa, rest of Africa, and internationally. It operates through three segments: ICT Distribution, Services and Solutions, and Financial Services. The ICT Distribution segment imports, assembles, distributes, and sells hardware and software products in sub-Saharan African markets through reseller channels and retail chains. The Services and Solutions segment provides systems integration and ICT solutions, including cybersecurity, application development, and artificial intelligence, as well as undertakes projects in the renewable energy. The Financial Services segment offers finance solutions to business entities in the SMME and commercial sectors. The company was formerly known as Pinnacle Holdings Limited and changed its name to Alviva Holdings Limited in March 2017. Alviva Holdings Limited was incorporated in 1986 and is based in Midrand, South Africa.
Full ALVNF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.